

FOR IMMEDIATE RELEASE



PERTHERA AND ZERO ANNOUNCE THE DECODE YOUR PROSTATE CANCER PROGRAM

McLean, VA, November 27, 2017— [Perthera, Inc.](#), the leading Therapeutics Intelligence Company™, has announced its partnership with [ZERO](#), the leading nonprofit prostate cancer advocacy group in the USA, to form and launch the nationwide *Decode Your Prostate Cancer* program aimed to provide each prostate cancer patient with therapeutic treatment options precisely matched to their individual cancer.

"We are extremely pleased to work with the team at Zero. Perthera's mission is to provide cancer patients with precisely matched therapeutic treatment options specific to their individual cancer through our Perthera Report™. In joining forces with Zero, together we will bring a significant and effective new tool for doctors, hospitals and patients across the US to fight prostate cancer." Neal G. Koller, President & CEO, Perthera, Inc.

In a combined effort, Perthera and Zero have created the *Decode Your Prostate Cancer* program, giving ZERO-affiliated patients and their doctors and hospitals access to the Perthera Report which provides precisely matched therapeutic options ranked for the highest probability of best outcome. The Perthera Report will provide them with the best information for fighting their specific prostate cancer.

"One of the most significant recent breakthroughs in the fight against cancer is pinpointing the patient's tumor characteristics. The Perthera Report accomplishes this and more by providing ranked therapeutic options that have been reviewed by Perthera's expert and scientific tumor board. With this critical data; we're able to put men battling prostate cancer on the best individualized treatment pathway; getting them back to life with their families." Jamie Bears, President & CEO, ZERO - The End of Prostate Cancer.

One in eight American men will have prostate cancer during his lifetime. Prostate cancer is the third leading cause of cancer death among American men and is the most commonly diagnosed. Learn more about the *Decode Your Prostate Cancer* program at <https://zerocancer.org/get-support/decode-prostate-cancer/>.

ABOUT PERTHERA, INC.:

Perthera is the leading Therapeutic Intelligence Company advancing precision medicine through its Perthera Report, which precisely matches cancer patients with multiple therapeutic options ranked by highest probability of best outcome. www.perthera.com

About ZERO — The End of Prostate Cancer:

ZERO is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. ZERO is a 501(c)(3) philanthropic organization, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 84 cents of every dollar to research and programs. For more information, visit www.zerocancer.org

Contact Information:

Phil Robertson

+1 (703) 286-0780

phil.robertson@perthera.com

###

Safe Harbor Statement:

The statements in the press release that relate to Perthera, Inc. (the "Company") expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the Company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.